Tirzepatide
GYMINDA
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 285
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| RO7204239 low dose + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| RO7204239 medium dose + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| RO7204239 high dose + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.